Transcode Therapeutics, Inc. (RNAZ) stock
RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.30−0.04 (-3.35%)
Close on Nov 19, 2026Market cap $1.32MP/E –Yield –
Transcode Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Transcode Therapeutics's free cash flow for the twelve months ending Dec 31, 2024 was -$13.36M. For fiscal 2025 it was -$19.52M. The highest annual figure on record is -$5.52M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$19.52M | – |
| FY2024 | Dec 31, 2024 | -$13.36M | – |
| FY2023 | Dec 31, 2023 | -$18.11M | – |
| FY2022 | Dec 31, 2022 | -$15.86M | – |
| FY2021 | Dec 31, 2021 | -$5.52M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -$3.15M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.93M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.34M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.94M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.66M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.51M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.41M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.53M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.05M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.42M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.41M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.98M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.69M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.14M | – |
| Q2 FY2021 | Jun 30, 2021 | -$98.24K | – |
| Q1 FY2021 | Mar 31, 2021 | -$597.45K | – |
See a number that looks wrong?